Background: Cytomegalovirus (CMV) is a major cause of infection in the early period after
Introduction
Cytomegalovirus (CMV) is a major cause of infection in the first months after heart transplantation (HTx). The reported incidence of CMV disease ranges between 10% and 60% depending on donor-recipient mismatch in CMV serology and on intensity of immunosupression [1] [2] [3] . Besides to direct sequalae of infection, CMV viral load has been associated with indirect effects like an increased risk of opportunistic infections [1] [2] [3] , high incidence of acute graft rejection and/or cardiac allograft vasculopathy [4] [5] [6] . Intravenous ganciclovir has been shown to prevent CMV disease both in CMVseronegative [7] and CMV-seropositive [8] n ganciclovir with improved bioavailability has facilitated easier and more widespread use of CMV prophylaxis in these patients. As a universal prophylaxis in CMV-seronegative recipients of organs from seropositive donors, valganciclovir at dosage of 900 mg daily is equivalent to oral ganciclovir administered at a dose of 1000 mg three times daily [9] . Valganciclovir has also been studied in the setting of preemptive therapy in HTx recipients [10] . In such case the HTx recipients are monitored for early evidence of CMV replication and treated with antiviral therapy in case of documented viraemia. Universal prophylaxis might be more effective way preventing both direct and indirect effects of CMV infection than preemptive therapy. On the other hand, preemptive therapy could reduce drug costs and toxicity. However, there are limited data about efficacy of universal prophylaxis with valgancilovir in CMV-seropositive HTx recipients. Similarly, direct comparison of universal prophylaxis and preemptive therapy is not available in this population. Therefore, we conducted a prospective cohort study comparing the efficacy and safety of the universal CMV prophylaxis with the preemptive treatment in HTx recipients at risk of CMV infection.
2.
Methods and materials
Study protocol
This was a prospective single-center, case-control study. The inclusion criteria were as follows: de novo HTx, age of recipient above 18 years and an increased risk of CMV infection. The following combinations of CMV serology in a donor (D) and a recipient (R) were included: Rþ/DÀ, Rþ/Dþ and RÀ/Dþ. We excluded individuals who deceased before the 10th postoperative day. The other exclusion criteria comprised acute renal or liver failure, severe leukopenia or trombocytopenia and known hypersensitivity to ganciclovir or valganciclovir.
Study groups
In total, 44 individuals who underwent de novo HTx between November 2007 and December 2008 were screened. Out of this cohort, 41 patients were at risk of CMV infection (85%). Three individuals died early after HTx and another three refused to participate in the study. A total of 35 patients participated in the study. Seventeen HTx recipients at risk of CMV infection were prospectively enrolled in the universal prophylaxis group. The remaining 18 individuals received preemptive treatment of CMV infection. The whole study group had the same induction therapy with polyclonal anti-human thymocyte immunoglobulin (Thymoglobuline, Genzyme Polyclonals S.A.S, Marcy L' Etoile, France) 1.25 mg/kg day administered at the time of surgery and in the following 3-7 days until target through levels of tacrolimus were reached. Standard immunosupressive regimen consisted of tacrolimus with a target through level of 10-15 ng/ml, mycophenolate mophetil 2000 mg daily, and prednisone at an initial dose of 1 mg/ kg day with subsequent tapering to less than 0.3 mg/kg day at 1 month and 0.1 mg/kg day at 12 months after HTx. Both groups were followed using the same schedule of clinical and laboratory controls, as well as the institutional protocol of endomyocardial biopsy (EMB). Acute allograft rejection episodesZgrade Banff 3A were treated with intravenous methylprednisolone 1000 mg for 3 consecutive days.
Study treatment
The universal prophylaxis group was treated with 900 mg of oral valganciclovir once daily for 100 days starting within the first 10 days after HTx. The group of preemptive therapy was closely monitored to detect CMV viraemia and received valganciclovir only in case of CMV viraemia higher than 500 copies/ml. The terapeutic dosage of valganciclovir was 900 mg twice daily for 2-3 weeks until clearance of CMV viraemia followed by a prophylactic dose for next 3 months. Individuals with tissue invasive CMV disease were treated with intravenous ganciclovir 5 mg/kg twice daily for 3 weeks followed by a prophylactic dose of valganciclovir for next 3 months. In cases of impaired renal function, dosages of valganciclovir and ganciclovir were adjusted appropriately.
Follow-up
Presence of CMV disease, CMV viraemia, other infections and acute graft rejection, as well as adverse effects were analyzed at 3th, 6th and 12th months post-transplant. EMB were planned and performed according to the institutional protocol. In brief, patients underwent EMB every week until 30 days post-transplant, every 2 weeks until 3 months, every 1 month until 6 months, followed by EMB at 9th and 12th months after HTx. Biopsies were graded according to 1990 ISHLT classification (Banff classification) using the following scale: 0, 1A, 1B, 2, 3A, 3B, 4 [11] . Each EMB was accompanied with a clinical and laboratory control. Laboratory analysis included measurements of CMV-viraemia, blood count, serum creatinine and liver function tests (aspartate amino-transferase, alanine amino-transferase, g-glutamyltransferase and alkaline phosphatase).
The pre-transplant CMV serology status of recipients and donors was assessed using a commercial enzyme-linked immunoassay detecting specific IgG and IgM antibodies. CMV viraemia was measured in peripheral venous blood samples obtained into tubes containing ethylenediaminetetraacetic acid. The measurement of CMV DNA concentration was performed using a commercially available real-time polymerase chain reaction (Artus TM CMV RG PCR kit, Qiagen, Hilden, Germany).
Definitions
CMV infection was defined as presence of CMV viraemia 4500 copies/ml regardless of symptoms. For the purpose of statistical analysis, we divided CMV infection into asymptomatic CMV viraemia (a positive CMV PCR without signs or symptoms) and CMV disease (detectable CMV PCR with attributable symptoms). Leukopenia referred to white blood cell count of less than 4.0 Â 10 9 l -1 and trombocytopenia to platelet count of less than 150 Â 10 9 l -1 .
Statistical methods
Categorical data were expressed as percentages and compared using w 2 analysis. Continuous variables were expressed as a mean and standard deviation. They were compared using the Student t-test for paired and unpaired data or by the nonparametric Mann-Whitney test when appropriate. A p value o0.05 was considered statistically significant. Analysis was performed using the statistical software SPSS (Chicago, Illinois, USA) for Windows, version 17.0.
Ethics
The investigation conformed to the principles outlined in the Declaration of Helsinky. It was approved by the local human ethics committee. All subjects gave their written informed consent prior to the participation in the study. Table 1 shows the study population characteristics. The universal prophylaxis group and the preemptive therapy group were well matched. All recipients were CMV-seropositive. There was no case of Dþ/R-CMV mismatch, which indicated an intermediate risk of post-transplant CMV infection in our study group. Two patients died during follow-up. In the universal prophylaxis group, one patient died of intracerebral hemorrhage on the 16th postoperative day which was not related to treatment with valganciclovir. In the preemptive therapy group, one patient died of sepsis of unknown origin in the 6th postoperative week. The remaining 33 patients completed 12 months of follow-up.
Results

Efficacy of treatment
Compared with the preemptive therapy, universal prophylaxis with valganciclovir resulted in significant reduction of asymptomatic CMV viraemia during the first 3 months of follow-up: 2 pts (11.7%) vs. 10 pts (55.6%), p ¼ 0.006 ( Table 2 ). The relative risk reduction reached 80%. In addition, four individuals (22%) from the preemptive therapy group experienced a tissue invasive form of CMV disease, which was not observed in the universal prophylaxis group. These four cases included histologically proven CMV gastritis and CMV myocarditis (0-3 months of follow-up) and histologically proven CMV colitis and interstitial pneumonia with detection of CMV and pneumocystis jiroveci in bronchoalveolar lavage specimens (4-6 months of follow-up). Importantly, there was no increase in late-onset CMV infection after completion of valganciclovir prophylaxis. Three months after HTx, asymptomatic CMV infection affected about 12% of patients in both groups in each time period (Table 2) . During the follow up period, four cases of opportunistic infection were observed. Two of them occurred in the universal prophylaxis group. The first case was pneumocystis jiroveci pneumonia diagnosed at 7 weeks after HTx that resolved after cotrimoxazol treatment. The second case was pneumocystis jiroveci pneumonia complicated by invasive pulmonary aspergilosis at 8 weeks after HTx. It was successfully treated with cotrimoxazol and voriconazol. The remaining two cases of opportunistic infection appeared in the preemptive therapy group. One case comprised mixed CMV and pneumocystis jiroveci interstitial pneumonia at 4 months of follow-up, treated again with a combination of cotrimoxazol and voriconazol. The second case was invasive pulmonary aspergilosis diagnosed at 4 months of follow-up, successfully treated with itraconazol.
Interestingly, during the first 3 months of follow up, the universal prophylaxis group presented with lower incidence of acute cellular rejection grade Banff 2 compared with the preemptive therapy group [0 pts vs. 5 pts (27.8%), p ¼ 0.019]. Within 12 months of follow-up, only one patient (6.3%) from the universal prophylaxis group experienced one episode of acute cellular rejection, grade Banff 2. On the contrary, 7 pts (41.2%) from the preemptive therapy group had within the same time period a total of 10 episodes of acute cellular rejection grade Banff 2 (p ¼ 0.015).
Safety
Universal prophylaxis with valganciclovir was well tolerated by 14 individuals (87.5%) for the entire treatment period of 100 days. Valganciclovir had to be discontinued in 2 pts (12.5%) due to significant leukopenia and neutropenia on the 57th and 85th day of prophylaxis. In these two patients, the count Another two individuals experienced leukopenia that resolved after dose reduction of valganciclovir to 450 mg daily ( Table 3 ). The first case appeared on the 79th day (leukocytes 3.5 Â 10 9 l -1 , neutrophiles 2.13 Â 10 9 l -1 ), while the second case was diagnosed on the 83rd day (leukocytes 3.9 Â 10 9 l -1 , neutrophiles 2.11 Â 10 9 l -1 ). In the first 3 months, the prevalence of leukopenia in the universal prophylaxis group was higher (25%) than in the preemptive therapy group (0%). However, this difference did not reach statistical significance (p ¼ 0.089). Table 3 shows the other parameters of safety. We observed a mild elevation of aspartate amino-transferase in the universal prophylaxis group at 3 months. However, this elevation was only mild and did not exceed the upper limit of normal values in any patient. No other drug-related sideeffects were observed.
Discussion
The main findings of our study can be summarized as follows. First, universal prophylaxis was significantly more effective than preemptive treatment in reduction of subclinical CMV infection. Second, universal prophylaxis with valganciclovir was safe and tolerated by 83% of the study group for the entire treatment period of 100 days. Third, universal prophylaxis reduced incidence of acute graft rejection Banff 2 during the first 3 months post-transplant.
Comparison with previous studies
The first experience with preemptive treatment of CMV infection with valganciclovir was reported by Devyatko et al. [10] . Subsequently, Potena el al. [12] demonstrated in a cohort study that universal prophylaxis with valganciclovir compared with preemptive intravenous ganciclovir reduces CMV viral burden and prevents progression of cardiac allograft vasculopathy. In another study by the same author, an aggressive CMV prophylaxis in CMV R-/DþHTx patients decreased risk of CMV infection, acute graft rejection and progression of cardiac allograft vasculopathy below levels seen in CMV-seropositive HTx patients receiving standard prophylaxis [13] . The aggressive prophylaxis protocol consisted of CMV hyperimmune immunoglobulin plus 4 weeks of treatment with intravenous ganciclovir followed by 2 months of valganciclovir. Standard prophylaxis consisted of intravenous ganciclovir administered for 4 weeks. A direct comparison of universal prophylaxis and preemptive therapy with valganciclovir was performed by Khoury et al. [14] in a randomized study in renal transplant recipients. The study demonstrated greater efficacy of prophylactic valganciclovir given for 100 days to suppress subclinical CMV infection for 12 months than preemptive therapy. However, 22% of patients in the universal prophylaxis group experienced late-onset CMV viraemia. This occurred more frequently in individuals with pre-transplant serology CMV Dþ/RÀ (in 38%). A randomized trial in 364 CMV Dþ/RÀ solid organ transplant recipients compared valganciclovir 900 mg once daily with oral ganciclovir 1000 mg three times a day for 100 days [9] . Valganciclovir provided greater reduction of CMV viraemia associated with reduced occurrence of acute graft rejection. Nevertheless, this study demonstrated high incidence of lateonset CMV infection, which appeared approximately in 50% of these high risk patients after completion of prophylaxis. Our study extends the available evidence by direct comparison of universal prophylaxis and preemptive therapy with valganciclovir in CMV-seropositive HTx recipients. It confirms results of previous studies in terms of reduced incidence of CMV infection and acute allograft rejection achieved through universal prophylaxis. However, its results may not be applicable to individuals with pre-transplant CMV serology Dþ/RÀ. These recipients have a high risk of CMV infection and may need a combination of prophylactic approaches or prolonged prophylaxis with valganciclovir. Further studies are needed to elucidate the best management in these individuals. Moreover, prognostic impact of universal CMV prophylaxis can only be assessed in large randomized trials.
CMV infection as a trigger of acute graft rejection and cardiac allograft vasculopathy
There is a growing evidence supporting association between CMV infection, acute graft rejection and cardiac allograft vasculopathy. These complications are called indirect effects and belong to the main causes of death and retransplantation in HTx patients.
CMV infection is known to increase the risk of acute cellular rejection. Several mechanisms have been implicated in the inflammatory response to allograft triggered by CMV. They include altered expression of growth factors and cytokines, up-regulation of proinflammatory adhesion molecules and/or modulation of the nitric oxide synthase pathway [3, [15] [16] [17] [18] [19] . Even latent CMV infection has been shown in a murine model to be associated with disruption of allograft tolerance and increased intramyocardial expression of proinflammatory genes in allografts but not in isografts [20] . The resulting inflammatory response of the host contributes to endothelial cell injury and development of cardiac allograft vasculopathy [21] .
We observed a significant increase in incidence of acute allograft rejection grade Banff 2 in individuals receiving preemptive therapy of CMV. It seems that frequent subclinical CMV infection in this subgroup may have contributed to impaired allograft tolerance. Grade Banff 2 of acute cellular rejection is characterized by detection of one lymphocytic infiltrate with focal myocyte damage in EMB. This grade of acute rejection usually does not cause acute dysfunction of the allograft. However, destruction of myocytes at this stage may stimulate native and adaptive immune response and trigger higher grades of acute allograft rejection and/or cardiac allograft vasculopathy.
Study limitations
This study has several limitations. First, relatively small sample size and non-randomized study design may decrease the applicability of the results. Second, only CMV-seropositive HTx recipients were studied. Therefore, the study results should be applied in similar population. Third, the study design did not include quantitative assessment of cardiac allograft vasculopathy with intravascular ultrasound. Therefore, we cannot comment on the effects of CMV management on progression of cardiac allograft vasculopathy.
Conclusions
In comparison with preemptive anti CMV therapy, universal prophylaxis with valganciclovir in CMV-seropositive HTx Table 3 -Safety of the universal prophylaxis compared with the preemptive therapy. Leukopenia was defined as white blood cells count less than 4000 Â 
Abbreviations:
ALT, alanine amino-transferase; AST, aspartate amino-transferase; PT, preemptive therapy; S-Cr, serum creatinine; UP, universal prophylaxis; WBC, white blood cells count.P-value for comparison between the universal prophylaxis group and the preemptive therapy group at each period of follow-up was coded: po0.05 n , po0.01 nn .
C O R E T VA S A 5 4 ( 2 0 1 2 ) e 1 6 -e 2 1 e20 recipients reduced more effectively incidence of CMV infection and acute allograft rejection grade Banff 2 during the first 3 months after transplantation. Prophylactic treatment was well tolerated and safe.
